Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00091715 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II
A Phase 3 study of Pulmonary Hypertension, sponsored by Actelion.
- Completed
- Registry status
- Phase 3
- Development phase
- 185
- Enrollment target
- 20
- Study locations
NCT00091715 is a Phase 3 study of Pulmonary Hypertension that has completed, run by Actelion. The registered enrollment target is 185 participants, below the 611-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT00091715, a Phase 3 study of Pulmonary Hypertension, has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 185 participants
- Enrollment target
- 20
- Study locations
Study Summary
The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) Class III and IV, to patients suffering from PAH Class II.
Conditions Studied
Interventions
- DRUG placebo
- DRUG bosentan
Study Locations (20)
Other
- The Prince Charles Hospital - Brisbane
- Royal Prince Albert Hospital - Camperdown
- St. Vincent's Hospital - Darlinghurst
- General Hospital of Vienna - Vienna
- UZ Gasthuisberg - Leuven
- Queen Mary Hospital - Hong Kong
- Interni klinika VFN - Prague
- Marseille-Timone - Marseille
Alberta
- University of Calgary - Calgary
- University of Alberta - Edmonton
Ontario
- Victoria Medical Centre - Hamilton
- Toronto General Hospital - Toronto
Alabama
- University of Alabama-Birmingham - Birmingham
California
- Harbor UCLA Medical Center - Torrance
Massachusetts
- Tufts- New England Medical Center - Boston
Michigan
- University of Michigan - Ann Arbor
Ohio
- Cleveland Clinic Foundation - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2004-04 |
| Est. Completion | 2011-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00091715
The ClinicalTrials.gov registry entry for NCT00091715 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 611-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (70% lower). The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Hypertension appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00091715 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Alberta, Ontario.
Frequently Asked Questions
What is clinical trial NCT00091715 about?
NCT00091715 is a clinical study titled "Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II". The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) Class III and IV, to patients suffering from PAH Class II.
What is the current status of trial NCT00091715?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 185 participants. The study started on 2004-04. Estimated completion is 2011-02.
What conditions does trial NCT00091715 study?
This clinical trial studies the following conditions: Pulmonary Hypertension.
What interventions are being tested in trial NCT00091715?
The interventions under investigation include: placebo (DRUG), bosentan (DRUG).
Who is sponsoring clinical trial NCT00091715?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00091715 being conducted?
This trial has 20 study locations across Alabama, California, Massachusetts, Michigan, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
RECRUITING · Phase 3
-
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
RECRUITING · Phase 3
-
Safety and Efficacy of FETO in CDH Phase III
RECRUITING · Phase 3
-
Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)
COMPLETED · Phase 3
-
Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension
COMPLETED · Phase 3
-
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.